Evidence map›Paper›PMID 35846031›Full record

ArticleEJHaem2022

Phase Ib study of avadomide (CC-122) in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma.

Loretta J Nastoupil, John Kuruvilla, Julio C Chavez, Fontanet Bijou, Thomas E Witzig, Armando Santoro, Ian W Flinn, Carola Boccomini, Vaishalee P Kenkre, Paolo Corradini and 13 more

Registry-linked trialOpen access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJHaem, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02031419 (A Phase 1B, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02031419 phase1terminatednot on this map

A Phase 1B, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

TypeinterventionalSponsorCelgeneRan2013 to 2023Enrolled174ConditionsLymphoma, Large B-Cell, DiffuseArmsCC-122, CC-223, Rituximab, CC-292
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Induced proximity-based therapeutic modalities.Nature reviews. Drug discovery · 2026
    Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. CRL4Cancers · 2022
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 18 institutions in 5 countries.

Loretta J NastoupilDepartment of Lymphoma and Myeloma Division of Cancer Medicine MD Anderson Cancer Center The University of Texas Houston Texas USA.
John KuruvillaDivision of Medical Oncology and Hematology Princess Margaret Cancer Centre University of Toronto Toronto Ontario Canada.ORCID https://orcid.org/0000-0002-6117-320X
Julio C ChavezH. Lee Moffitt Cancer Center and Research Institute Tampa Florida USA.
Fontanet BijouInstitut Bergonié Bordeaux Cedex France.
Thomas E WitzigMayo Clinic Rochester Minnesota USA.
Armando SantoroDepartment of Biomedical Sciences Pieve Emanuele Milan Humanitas University Italy -IRCCS Humanitas Research Hospital- Humanitas Cancer Center Rozzano Milan Italy.
Ian W FlinnSarah Cannon Research Institute Nashville Tennessee USA.
Carola BoccominiSC Ematologia ASOU Città della Salute e della Scienza di Torino Turin Italy.
Vaishalee P KenkreDivision of Hematology and Oncology University of Wisconsin Madison Wisconsin USA.
Paolo CorradiniIRCCS Istituto Nazionale dei Tumori University of Milano Milano Italy.
Iris IsufiYale Cancer Center New Haven Connecticut USA.
David J AndorskyRocky Mountain Cancer Centers The US Oncology Network Boulder Colorado USA.
Leonard M KleinIllinois Cancer Specialists The US Oncology Network Niles Illinois USA.
Daniel R GreenwaldCancer Center of Santa Barbara Santa Barbara California USA.
Randeep SanghaCross Cancer Institute Edmonton Alberta Canada.
Frank ShenBristol Myers Squibb Princeton New Jersey USA.
Patrick HagnerBristol Myers Squibb Princeton New Jersey USA.
Yan LiBristol Myers Squibb Princeton New Jersey USA.
Juergen DobmeyerCentre for Innovation and Translational Research Europe (CITRE) Bristol-Myers Squibb Company Seville Spain.
Nian GongBristol Myers Squibb Princeton New Jersey USA.
Shailaja UttamsinghBristol Myers Squibb Princeton New Jersey USA.
Michael PourdehnadBristol Myers Squibb Princeton New Jersey USA.
Vincent RibragInstitut Gustave Roussy Villejuif France.ORCID https://orcid.org/0000-0002-5221-353X
Bristol-Myers Squibb (United States) · USAlberta Cancer Foundation · CAAzienda Ospedaliera Citta' della Salute e della Scienza di Torino · ITBristol-Myers Squibb (Belgium) · BECancer Care Specialists of Illinois · USHumanitas University · ITInstitut Bergonié · FRInstitut Gustave Roussy · FRMayo Clinic · USMoffitt Cancer Center · USRocky Mountain Cancer Centers · USSanta Barbara City College · USSarah Cannon · USThe University of Texas MD Anderson Cancer Center · USUniversity of Milan · ITUniversity of Toronto · CAUniversity of Wisconsin–Madison · USYale Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The multicenter, phase Ib CC-122-DLBCL-001 dose-expansion study (NCT02031419) explored the cereblon E3 ligase modulator (CELMoD) agent avadomide (CC-122) plus rituximab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL). Patients received avadomide 3 mg/day 5 days on/2 days off plus rituximab 375 mg/m

Indexed as

avadomideCELMoDdiffuse large B‐cell lymphomafollicular lymphoma

Identifiers

PMID35846031
PMCPMC9175947
OpenAlexW4212971766

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.